Impact of Efavirenz-, Ritonavir-Boosted Lopinavir-, and Nevirapine-Based Antiretroviral Regimens on the Pharmacokinetics of Lumefantrine and Safety of Artemether-Lumefantrine in Plasmodium falciparum-Negative HIV-Infected Malawian Adults Stabilized on Antiretroviral Therapy

Antimicrobial Agents and Chemotherapy
Clifford G BandaVictor Mwapasa

Abstract

There is conflicting evidence of the impact of commonly used antiretroviral therapies (ARTs) on the pharmacokinetics of lumefantrine and the safety profile of artemether-lumefantrine. We compared the area under the concentration-time curve from 0 h to 14 days (AUC0-14 days) of lumefantrine and the safety profile of artemether-lumefantrine in malaria-negative human immunodeficiency virus (HIV)-infected adults in two steps. In step 1, a half-dose adult course of artemether-lumefantrine was administered as a safety check in four groups (n = 6/group): (i) antiretroviral naive, (ii) nevirapine-based ART, (iii) efavirenz-based ART, and (iv) ritonavir-boosted lopinavir-based ART. In step 2, a standard-dose adult course of artemether-lumefantrine was administered to a different cohort in three groups (n = 10 to 15/group): (i) antiretroviral naive, (ii) efavirenz-based ART, and (iii) ritonavir-boosted lopinavir-based ART. In step 1, lumefantrine's AUC0-14 days was 53% (95% confidence interval [CI], 0.27 to 0.82) lower in the efavirenz-based ART group than in the ART-naive group and was 2.4 (95% CI, 1.58 to 3.62) and 2.9(95% CI, 1.75 to 4.72) times higher in the nevirapine- and ritonavir-boosted lopinavir groups, respectively. In step 2,...Continue Reading

References

Feb 19, 2000·Antimicrobial Agents and Chemotherapy·F EzzetN J White
Oct 1, 2003·Annals of Noninvasive Electrocardiology : the Official Journal of the International Society for Holter and Noninvasive Electrocardiology, Inc·L S Fridericia
Feb 26, 2004·Antimicrobial Agents and Chemotherapy·Diane T HollandUNKNOWN Adult and Pediatric AIDS Clinical Trials Group Pharmacology Laboratory Committees, Pediatric AIDS Clinical Trials Group
Jan 20, 2005·European Journal of Clinical Pharmacology·Jacques FellayChin B Eap
Jan 28, 2005·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Cuyue TangAnthony Y H Lu
Dec 3, 2005·The Journal of Infectious Diseases·Moses R KamyaDiane Havlir
Feb 16, 2006·The Journal of Infectious Diseases·Miriam K LauferChristopher V Plowe
May 3, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ric N PriceFrançois Nosten
Jul 26, 2006·Expert Opinion on Drug Metabolism & Toxicology·Qing MaGene D Morse
Sep 9, 2006·The Journal of Infectious Diseases·Jean-Pierre Van GeertruydenUmberto D'Alessandro
Dec 14, 2006·Expert Opinion on Pharmacotherapy·Gilbert KokwaroAlexis Nzila
Dec 21, 2006·Tropical Medicine & International Health : TM & IH·Mey Bouth DenisPascal Ringwald
Feb 16, 2007·Tropical Medicine & International Health : TM & IH·Elizabeth A AshleyFrançois Nosten
Sep 8, 2007·Malaria Journal·Karen I BarnesNicholas J White
Mar 21, 2008·Trends in Parasitology·Nicholas J WhiteJulie Simpson
May 1, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Anne F GasasiraGrant Dorsey
Jun 10, 2009·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Polina GermanFrancesca T Aweeka
Jun 12, 2009·Drug Metabolism Reviews·Shu-Feng ZhouBalram Chowbay
Aug 8, 2009·British Journal of Clinical Pharmacology·Vanitha SekarRichard M W Hoetelmans
Feb 10, 2012·The Journal of Antimicrobial Chemotherapy·Pauline Byakika-KibwikaConcepta Merry
Jun 13, 2012·The Journal of Antimicrobial Chemotherapy·Pauline Byakika-KibwikaConcepta Merry
Aug 25, 2012·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Liusheng HuangFrancesca T Aweeka
Nov 30, 2012·The New England Journal of Medicine·Jane AchanMoses R Kamya
Oct 10, 2014·British Journal of Clinical Pharmacology·Richard M HoglundJoel Tarning
Sep 24, 2015·Antimicrobial Agents and Chemotherapy·Sunil ParikhKimberly K Scarsi
Dec 31, 2015·Malawi Medical Journal : the Journal of Medical Association of Malawi·M R ChisaleV Mwapasa

❮ Previous
Next ❯

Software Mentioned

Stata

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.